Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Multicenter, Dose-exploration Study of Visilizumab in Subjects With Intravenous Steroid-refractory Ulcerative Colitis

NCT00307827 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00307827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00307827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Multicenter, Dose-exploration Study of Visilizumab in Subjects With Intravenous Steroid-refractory Ulcerative Colitis
Lead sponsor
Abbott
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2006
Completion date
November 30, 2007
Enrollment
38 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis